Belgian legislation for ATMPs at a glance
About 2 years ago a milestone was set in the Belgian Advanced Therapy Medicinal Products (“ATMP”) legislation. On October 30th 2018, a modification of the law of December 19th 2008, regarding the collection and use of human body material for the purpose of human therapeutic applications or scientific research, was published. This law enables progress in the development of new, innovative therapies based upon the handling of human cells and tissues for the production of medicines. Discover the most important elements of this law in the webinar.
The Speaker
Marc Martens
Marc Martens is board member of bio.be and partner of Bird & Bird. He is co-head of Bird & Bird’s International Life Sciences & Healthcare group and head of Bird & Bird’s Regulatory, Public & Administrative Law group in Brussels. He holds a law degree from the Vrije Universiteit Brussel (VUB). Before joining Bird & Bird, he was an expert adviser to the Vice-Prime Minister of Belgium for 3 years.
The Sponsor
essenscia/bio.be
bio.be is the Belgian federation representing the biotech and the life sciences industry. It operates under the aegis of umbrella organisation essenscia. Bio.be’s members are part of an effective advocacy and regulatory voice representing the collective interests of the Belgian life sciences and biotechnology community. Bio.be has the tools to help its members’ business reach its full potential through advocacy, communications and membership services.